Stock ALZN ALZAMEND NEURO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Alzamend Neuro, Inc. Stock

Equities

ALZN

US02262M4078

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.7256 USD +5.93% Intraday chart for Alzamend Neuro, Inc. +0.21% -18.47%
Mar. 25 Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Jan. 31 Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC CI

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 4.7M
Net income 2024 * -11M Net income 2025 * -18M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.4 x
P/E ratio 2025 *
-0.47 x
Employees 6
Yield 2024 *
-
Yield 2025 *
-
Free-Float 70.36%
More Fundamentals * Assessed data

Chart Alzamend Neuro, Inc.

Dynamic Chart

Latest news about Alzamend Neuro, Inc.

Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024 CI
Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC CI
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman CI
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023 CI
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients CI
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate MT
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment DJ
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients CI
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001 CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting MT
Alzamend Neuro Seeks FDA Nod to Start Trial in Major Depressive Disorder MT
Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001 CI
Alzamend Neuro, Inc Receives FDA ?Study May Proceed? Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients CI
Alzamend Neuro Secures Extension to Regain Compliance With Nasdaq's Minimum Bid Price Rule MT
Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023 CI
More news

Analyst Recommendations on Alzamend Neuro, Inc.

Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target MT
Ascendiant Capital Adjusts Price Target on Alzamend Neuro to $8.25 From $8, Maintains Buy Rating MT
ALZAMEND NEURO : Ascendiant Capital Initiates Alzamend Neuro at Buy Rating With $8 Price Target MT
More recommendations

Press releases Alzamend Neuro, Inc.

Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients AQ
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients BU
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients BU
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement AQ
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement BU
More press releases

Quotes and Performance

1 day+5.93%
1 week-4.81%
Current month-27.44%
1 month-28.16%
3 months-17.95%
6 months-75.80%
Current year-18.47%
More quotes

Highs and lows

1 week
0.65
Extreme 0.6516
0.77
1 month
0.65
Extreme 0.6516
1.07
Current year
0.65
Extreme 0.6516
1.29
1 year
0.65
Extreme 0.6516
11.91
3 years
0.65
Extreme 0.6516
503.25
5 years
0.65
Extreme 0.6516
503.25
10 years
0.65
Extreme 0.6516
503.25
More quotes

Managers and Directors - Alzamend Neuro, Inc.

Managers TitleAgeSince
Stephan Jackman CEO
 Chief Executive Officer 48 18-11-19
David Katzoff DFI
 Director of Finance/CFO 63 19-10-31
William Horne CHM
 Chairman 55 16-05-31
Members of the board TitleAgeSince
Mark Gustafson BRD
 Director/Board Member 64 21-05-31
Todd Ault FOU
 Founder 54 16-02-24
William Horne CHM
 Chairman 55 16-05-31
More insiders

Quotes

Date Price Change Volume
24-04-22 0.685 +1.41% 48,454
24-04-19 0.6755 -2.24% 28,688
24-04-18 0.691 -4.57% 27,697
24-04-17 0.7241 -5.01% 59,045
24-04-16 0.7623 +2.87% 54,621

Delayed Quote Nasdaq, April 23, 2024 at 04:00 pm EDT

More quotes

Company Profile

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's through a royalty-bearing exclusive worldwide license from the Licensor.
Sector
Biotechnology & Medical Research
Calendar
2024-04-30 - Annual General Meeting
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
0.685 USD
Average target price
21 USD
Spread / Average Target
+2,965.69%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALZAMEND NEURO, INC. Stock Alzamend Neuro, Inc.
-18.47% 4.7M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 40.08B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 40B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 26.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 24.58B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 11.66B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.01B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALZN Stock